{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:57:06Z","timestamp":1787803026413,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RA) are prescribed for glycemic control and weight reduction. Little is known regarding the impact of GLP-1RAs on bone health in patients without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective case-control study was conducted using data from TriNetX database between 2015 and 2022. The primary objective was to assess fracture risk in overweight and obese patients without diabetes following GLP-1RA use. Patients with an ICD-10 diagnosis of overweight or obesity were included. Patients with diabetes or an increased risk of fragility fractures were excluded. An initial query resulted in 1,155,496 patients with 606,364 available for analysis. This cohort was divided into (1) those with GLP-1RA prescriptions (n = 33,220) and (2) those without GLP-1RA prescriptions (n = 593,748). Propensity matching was done for these groups (n = 33,210 each) at the time of prescription. The primary outcome was fracture diagnosis within 1 year of GLP-1RA prescription. Risk and odds ratio (OR) with 95% confidence intervals (CIs) were estimated using multiple logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fracture risk was significantly increased in overweight and obese patients without diabetes who were prescribed a GLP-1RA compared with patients who were not (3.05% vs. 2.61%, number needed to harm [NNH] = 227, OR 1.19, CI [1.09 to 1.31]; risk ratio 1.09 CI [1.04 to 1.14]). Subanalyses based on body mass index (BMI) and age group demonstrated increased fracture risk in the GLP-1RA group in patients with a BMI \u226540 (3.15% vs. 1.91%, NNH = 81, OR 1.26, CI [1.04 to 1.52]) and those older than 67 years, including those aged 68 to 77 years (5.61% vs. 3.65%, NNH = 51, OR 2.25, CI [1.62 to 3.13]) and 78 to 88 years (9.28% vs. 5.10%, NNH = 24, OR 4.99, CI [2.68 to 9.26]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GLP-1RA use was associated with increased fracture risk in nondiabetic patients who were overweight or obese. Subgroup analysis demonstrated that only those with BMI \u226540 and age \u226568 years were found to have a significant increase in fracture risk. Further research is necessary to guide GLP-1RA prescriptions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-24-01505","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:00:28Z","timestamp":1766440828000},"page":"e1610-e1619","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients"],"prefix":"10.5435","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7312-723X","authenticated-orcid":false,"given":"Evangelia","family":"Constantine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Enthoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Pflug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5889-0558","authenticated-orcid":false,"given":"Alexander","family":"Lauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"3361309","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-Week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","volume":"24","author":"Dailey","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/medicina58020224","article-title":"The impact of GLP1 agonists on bone metabolism: A systematic review","volume":"58","author":"Daniilopoulou","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"580","DOI":"10.21037\/atm.2019.09.51","article-title":"Effect of type 2 diabetes medications on fracture risk","volume":"7","author":"Guja","year":"2019","journal-title":"Ann Transl Med"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","article-title":"Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice","volume":"81","author":"Pereira","year":"2015","journal-title":"Bone"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","article-title":"Glucagon-like peptide-1 receptor agonists and fracture risk: A network meta-analysis of randomized clinical trials","volume":"29","author":"Zhang","year":"2018","journal-title":"Osteoporos Int"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: A meta-analysis of randomized controlled trials","volume":"48","author":"Su","year":"2015","journal-title":"Endocrine"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/JOE-13-0146","article-title":"Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor","volume":"219","author":"Mabilleau","year":"2013","journal-title":"J Endocrinol"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","article-title":"Narrative review of effects of glucagon-like Peptide-1 receptor agonists on bone health in people living with obesity","volume":"114","author":"Herrou","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2016.153","article-title":"Mechanisms of diabetes mellitus-induced bone fragility","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.12998\/wjcc.v9.i33.10064","article-title":"Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia","volume":"9","author":"Ma","year":"2021","journal-title":"World J Clin Cases"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(24)00163-3","article-title":"Bone health in adults with obesity before and after interventions to promote weight loss","volume":"12","author":"Paccou","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","article-title":"Major osteoporotic fragility fractures: Risk factor updates and societal impact","volume":"7","author":"Pisani","year":"2016","journal-title":"World J Orthop"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/endrev\/bnab028","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling","year":"2022","journal-title":"Endocr Rev"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: rxNorm at 6 years","volume":"18","author":"Nelson","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"R25-20260605","article-title":"_marginaleffects: Predictions, comparisons, slopes, marginal means, and hypothesis tests","author":"V","year":"2024"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","article-title":"Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials","volume":"6","author":"Mabilleau","year":"2014","journal-title":"J Diabetes"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: A randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-021-06206-9","article-title":"Fracture risk following bariatric surgery: A systematic review and meta-analysis","volume":"33","author":"Saad","year":"2022","journal-title":"Osteoporos Int"},{"key":"R30-20260605","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs glucagon-like Peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: A systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"R31-20260605","doi-asserted-by":"crossref","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R32-20260605","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and Improvement in comorbidity: Differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"R33-20260605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R34-20260605","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1186\/s12889-023-15940-0","article-title":"Risk of fracture according to temporal changes of low body weight changes in adults over 40 years: A nationwide population-based cohort study","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Public Health"},{"key":"R35-20260605","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.nutr.012809.104655","article-title":"Bone metabolism in obesity and weight loss","volume":"32","author":"Shapses","year":"2012","journal-title":"Annu Rev Nutr"},{"key":"R36-20260605","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1573399816666200705210006","article-title":"Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus","volume":"17","author":"Ida","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"R37-20260605","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i4.50","article-title":"Mechanical signaling for bone modeling and remodeling","volume":"19","author":"Robling","year":"2009","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"R38-20260605","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","article-title":"Mechanical regulation of bone remodeling","volume":"10","author":"Wang","year":"2022","journal-title":"Bone Res"},{"key":"R39-20260605","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R40-20260605","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jn\/136.6.1453","article-title":"Bone, body weight, and weight reduction: What are the concerns?","volume":"136","author":"Shapses","year":"2006","journal-title":"J Nutr"},{"key":"R41-20260605","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"R42-20260605","doi-asserted-by":"crossref","first-page":"101758","DOI":"10.1016\/j.berh.2022.101758","article-title":"Modifiable risk factors for bone health & fragility fractures","volume":"36","author":"Wilson-Barnes","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:41:43Z","timestamp":1787668903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-24-01505","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2024-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}